News
2 October
2026

Data from uniQure’s (NASDAQ) therapy indicate why the next generation of Huntington’s disease therapies should be selective

Selectivity is a feature of the therapy developed by multiQure

The latest four-year data on the AMT-130 gene therapy just announced by uniQure (NASDAQ) are important for the entire field of Huntington’s disease treatment. On the one hand, the data confirm that lowering huntingtin levels can affect the course of the disease by slowing its progression; on the other hand, they also point to the importance of the “selectivity” of the therapeutic effect as a key criterion for assessing a therapy’s efficacy. These conclusions are particularly significant for multiQure – a WSE-listed company developing a selective RNAi gene therapy designed to silence the mutant HTT gene while sparing its normal copy.

The new results announced by uniQure point to an approximately 80% slowing of disease progression during the first 3 years after the procedure, but this effect drops to just 44% in the fourth year. For multiQure (WSE), the most important takeaway from the new data is the significance of therapy selectivity. In particular:

  1. uniQure’s therapy (AMT-130) lowers the levels of both the mutant huntingtin responsible for the development of the disease and its normal form, which performs important functions in nerve cells.
  2. multiQure, by contrast, adopted a different priority for its therapy from the outset: to silence primarily the disease-causing, mutant version of the HTT gene, leaving its normal copy as intact as possible. The RNAi technology being advanced by multiQure was designed specifically with such allele selectivity in mind, and with a view to limiting a potential weakness of uniQure’s therapy.

In multiQure’s view, the future of Huntington’s disease therapies may lie not only in lowering huntingtin levels, but also in precisely silencing its disease-causing form. “In our opinion, the latest uniQure data reinforce the importance of the approach that multiQure adopted as its main guiding principle already at the design stage of its therapy” – says Prof. Paul Lewicki, Member of the Supervisory Board and co-founder of multiQure S.A.

In summary, uniQure’s data confirm that lowering huntingtin levels can slow the course of the disease, while also showing how much the selectivity of a therapy matters. multiQure believes that silencing only the mutant HTT gene while preserving its normal copy is the direction in which the next generation of Huntington’s disease therapies should develop. The Company plans to verify this approach in patients – the first use of the therapy is planned for the second half of 2027.

Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

multiQure